Wells Fargo (WFC) concluded the recent trading session at $57.93, signifying a -0.74% move from its prior day's close.
Wells Fargo (WFC) faces a class action lawsuit due to its alleged involvement in the $300 million Ponzi scheme from 2011 to 2021.
Wells Fargo (WFC) introduces Attune World Elite Mastercard. With 4% unlimited cash rewards on all eligible purchases, the card is likely to stand out among peer offerings.
Making their way onto the Zacks Rank #1 (Strong Buy) list now appears to be a good time to consider a pair of big bank stocks in Bank of America (BAC) and Wells Fargo (WFC).
Wells Fargo (WFC) will likely gain from strong liquidity and balance sheet position. Also, cost-efficiency initiatives aid bottom-line growth.
Wells Fargo (WFC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Wells Fargo (WFC) reachead $59.34 at the closing of the latest trading day, reflecting a -0.97% change compared to its last close.
Wells Fargo has faced multiple scandals and asset caps imposed by the FED, but its stock has doubled the returns of the S&P 500 YTD. The company had strong 1Q earnings, with revenue increasing and net income of $4.6 billion, resulting in a low P/E ratio of ~13. Wells Fargo continues to run a major business with diversified consumer and commercial loans, maintaining strong credit quality and the ability to generate substantial shareholder returns.
Wells Fargo (WFC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Wells Fargo CEO Charlie Scharf reportedly told investors Wednesday (May 29) that the bank could be doing more corporate lending and trading if regulators lifted the asset cap that they imposed on it. Regulators put the $1.
Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. I highlight three of my favorite equities on Wells Fargo's report that I currently hold in my personal accounts in the paragraphs below.
Charlie Scharf told business leaders that the bank's operating committee agrees on the need for more efficiency.